Melasma (Facial Melasma)
7
2
2
2
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 7 trials
100.0%
+13.5% vs benchmark
14%
1 trials in Phase 3/4
0%
0 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (7)
Comparison of Efficacy of Topical Westerhoff Formula Cream Vs Topical 4% Hydroquinone for the Treatment of Melasma
Comparative Evaluation of Topical 30% Metformin and Kligman's Regimen in Women With Melasma
Azelaic Acid 20% vs Hydroquinone 4% in Epidermal Melasma
Expert Consensus on the Clinical Management of Melasma: A Delphi Method Study
Ultrasound-Enhanced Delivery of Compound TXA Solution in Melasma
Oral Melatonin Versus Oral Tranexamic Acid in the Management of Melasma
COMPARISON OF A COSMETIC SERUM AND 4% HYDROQUINONE FOR TREATING MELASMA OVER 84 DAYS